Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®

被引：111

作者：

Kaku, Kohei ^{[1
]}

Lee, Jisoo ^{[2
]}

Mattheus, Michaela ^{[2
]}

Kaspers, Stefan ^{[2
]}

George, Jyothis ^{[3
]}

Woerle, Hans-Juergen ^{[2
]}

Aizenberg, D. ^{[4
]}

Ulla, M. ^{[5
]}

Waitman, J. ^{[6
]}

De Loredo, L. ^{[7
,8
]}

Farias, J. ^{[9
]}

Fideleff, H. ^{[9
]}

Lagrutta, M. ^{[10
]}

Maldonado, N. ^{[11
]}

Colombo, H. ^{[12
]}

Ferre Pacora, F. ^{[13
]}

Wasserman, A. ^{[14
]}

Maffei, L. ^{[15
]}

Lehman, R. ^{[16
]}

Selvanayagam, J. ^{[17
]}

d'Emden, M. ^{[18
]}

Fasching, P. ^{[19
]}

Paulweber, B. ^{[20
]}

Toplak, H. ^{[21
]}

Luger, A. ^{[22
]}

Drexel, H. ^{[23
]}

Prager, R. ^{[24
]}

Schnack, C. ^{[25
]}

Schernthaner, G. ^{[25
,26
]}

Fliesser-Goerzer, E.

Kaser, S. ^{[27
]}

Scheen, A. ^{[28
]}

Van Gaal, L. ^{[29
]}

Hollanders, G.

Kockaerts, Y. ^{[30
]}

Capiau, L.

Chachati, A. ^{[31
]}

Persu, A. ^{[32
]}

Hermans, M. ^{[32
]}

Vantroyen, D. ^{[33
]}

Vercammen, C. ^{[34
]}

Van de Borne, P. ^{[35
]}

Mathieu, C. ^{[36
]}

Benhalima, K. ^{[36
]}

Lienart, F. ^{[37
]}

Mortelmans, J.

Strivay, M. ^{[38
]}

Vereecken, G.

Keymeulen, B. ^{[39
]}

Lamkanfi, F. ^{[39
]}

机构：

[1] Kawasaki Med Sch, Dept Gen Internal Med, 577 Matsushima, Kurashiki, Okayama 7010192, Japan

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England

[4] Ctr Med Viamonte, Buenos Aires, DF, Argentina

[5] ILAIMCEOM, Cordoba, Cba, Argentina

[6] Ctr Diabetol Dr Waitman, Cordoba, Cba, Argentina

[7] Hosp Privado Ctr Med Cordoba SA, Cordoba, Cba, Argentina

[8] Parque Velez Sarfield, Cordoba, Cba, Argentina

[9] Sanatorio Guemes Hosp Privado, Buenos Aires, DF, Argentina

[10] Inst Invest Clin, Rosario, Santa Fe, Argentina

[11] Ctr Med Alta Complejidad, Rosario, Santa Fe, Argentina

[12] Clin Privada Colombo, Cordoba, Co, Argentina

[13] Ctr Med Colon, Cordoba, Co, Argentina

[14] Fepreva, Buenos Aires, DF, Argentina

[15] Consultorios Asociados Endocrinol & Invest Clin, Buenos Aires, DF, Argentina

[16] Adelaide Med Res, Ashford, SA, Australia

[17] Heart & Vasc Inst, Fullarton, SA, Australia

[18] Royal Brisbane & Womens Hosp, Herston, Qld, Australia

[19] Wilhelminenspital Wien, Vienna, Austria

[20] LKH Salzburg, St Johanns Spital, Salzburg, Austria

[21] Med Univ Graz, Graz, Austria

[22] Univ Klin Innere Med III, Vienna, Austria

[23] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[24] Krankenhaus Hietzing NZR, Vienna, Austria

[25] Krankenanstalt Rudolfstiftung Wien, Semmelweis Frauenklin, Vienna, Austria

[26] Univ Klin Innere Med II, Vienna, Austria

[27] Univ Klin Innsbruck, Innsbruck, Austria

[28] Ctr Hosp Univ Liege, Liege, Belgium

[29] UZA, Edegem, Belgium

[30] Ziekenhuis Oost Limburg, Genk, Belgium

[31] CHR Huy, Huy, Belgium

[32] Clin Univ St Luc, Brussels, Belgium

[33] Huisartsenpraktijk Hygeia, Hasselt, Belgium

[34] Imelda ZH Bonheiden, Bonheiden, Belgium

[35] Hop Univ Erasme, Brussels, Belgium

[36] Univ Hosp Gasthuisberg, Leuven, Belgium

[37] CHU Tivoli, La Louviere, Belgium

[38] CHR Citadelle, Site Citadelle, Liege, Belgium

[39] UZ Brussels, Brussels, Belgium

[40] Hosp Sao Paulo UNIFESP, Villa Clementino, SP, Brazil

[41] Ctr Pesquisas Clin Ltda, Higienopolis, SP, Brazil

[42] Hosp Rim Hipertensao, Vila Clementino, SP, Brazil

[43] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil

[44] Blumenau Serv Med SC Ltda, Vila Leopoldina, SP, Brazil

[45] Irmandade Santa Casa Misericordia Sao Paulo, Vila Albuquerque, SP, Brazil

[46] Hosp Guilherme Alvaro, Ctr Pesquisas Clin, Boqueirao, ST, Brazil

[47] Hosp Mae Deus, Porto Alegre, RS, Brazil

[48] Hosp Geral Goiania, Goiania, Go, Brazil

[49] FMUSP, Hosp Clin Sao Paulo, Sao Paulo, Brazil

[50] Univ Ribeirao Preto, Hosp Elect Bonini, Ribeirao Preto, Brazil

来源：

CIRCULATION JOURNAL | 2017年 / 81卷 / 02期

关键词：

Diabetes mellitus; Mortality; Race; Sodium-glucose cotransporter 2; Treatment outcomes; INHIBITION;

D O I：

10.1253/circj.CJ-16-1148

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: In the EMPA-REG OUTCOME (R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) and established CV disease. We investigated the effects of empagliflozin in patients of Asian race. Methods and Results: Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Of 7,020 patients treated, 1,517 (21.6%) were of Asian race. The reduction in 3-point MACE in Asian patients was consistent with the overall population: 3-point MACE occurred in 79/1,006 patients (7.9%) in the pooled empagliflozin group vs. 58/511 patients (11.4%) in the placebo group (hazard ratio: 0.68 [95% confidence interval: 0.48-0.95], P-value for treatment by race interaction (Asian, White, Black/African-American): 0.0872). The effects of empagliflozin on the components of MACE, all-cause mortality, and heart failure outcomes in Asian patients were consistent with the overall population (P-values for interaction by race >0.05). The adverse event profile of empagliflozin in Asian patients was similar to the overall trial population. Conclusions: Reductions in the risk of CV outcomes and mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with the overall trial population.

引用

页码：227 / +

页数：11

共 15 条

[1] Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].

Cherney, David Z. I. ;

Perkins, Bruce A. ;

Soleymanlou, Nima ;

Maione, Maria ;

Lai, Vesta ;

Lee, Alana ;

Fagan, Nora M. ;

Woerle, Hans J. ;

Johansen, Odd Erik ;

Broedl, Uli C. ;

von Eynatten, Maximilian .

CIRCULATION, 2014, 129 (05) :587-597

[2] Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes [J].

Chilton, R. ;

Tikkanen, I. ;

Cannon, C. P. ;

Crowe, S. ;

Woerle, H. J. ;

Broedl, U. C. ;

Johansen, O. E. .

DIABETES OBESITY & METABOLISM, 2015, 17 (12) :1180-1193

[3] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Hantel, Stefan ;

Salsali, Afshin ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

EUROPEAN HEART JOURNAL, 2016, 37 (19) :1526-1534

[4] Health Disparities in Endocrine Disorders: Biological, Clinical, and Nonclinical Factors-An Endocrine Society Scientific Statement [J].

Golden, Sherita Hill ;

Brown, Arleen ;

Cauley, Jane A. ;

Chin, Marshall H. ;

Gary-Webb, Tiffany L. ;

Kim, Catherine ;

Sosa, Julie Ann ;

Sumner, Anne E. ;

Anton, Blair .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (09) :E1579-E1639

[5] Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes [J].

Heise, Tim ;

Jordan, Jens ;

Wanner, Christoph ;

Heer, Martina ;

Macha, Sreeraj ;

Mattheus, Michaela ;

Lund, Soren S. ;

Woerle, Hans J. ;

Broedl, Uli C. .

CLINICAL THERAPEUTICS, 2016, 38 (10) :2265-2276

[6] Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus [J].

Heise, Tim ;

Jordan, Jens ;

Wanner, Christoph ;

Heer, Martina ;

Macha, Sreeraj ;

Mattheus, Michaela ;

Lund, Soren S. ;

Woerle, Hans J. ;

Broedl, Uli C. .

CLINICAL THERAPEUTICS, 2016, 38 (10) :2248-2264

[7] Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States [J].

Ma, Ronald C. W. ;

Chan, Juliana C. N. .

YEAR IN DIABETES AND OBESITY, 2013, 1281 :64-91

[8] Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus [J].

Neeland, Ian J. ;

McGuire, Darren K. ;

Chilton, Robert ;

Crowe, Susanne ;

Lund, Soren S. ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Johansen, Odd Erik .

DIABETES & VASCULAR DISEASE RESEARCH, 2016, 13 (02) :119-126

[9] Rising Burden of Obesity in Asia [J].

Ramachandran, Ambady ;

Snehalatha, Chamukuttan .

JOURNAL OF OBESITY, 2010, 2010

[10] Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial [J].

Ridderstrale, Martin ;

Andersen, Knut Robert ;

Zeller, Cordula ;

Kim, Gabriel ;

Woerle, Hans J. ;

Broedl, Uli C. .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (09) :691-700

← 1 2 →